HIGHLIGHTS
- who: Min-Kyung Yeo and colleagues from the Department of Pathology, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea have published the research: HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies, in the Journal: (JOURNAL)
- what: In a phase 2 clinical trial of trastuzumab in 41 patients with recurrent or refractory ovarian or primary peritoneal carcinoma and HER2 expression scores of 2 or 3, the overall objective response rate was 7.3% (one complete response and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.